GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis
Executive Summary
GlaxoSmithKline's creation of a separate "GSK Oncology" R&D unit is not only intended to capture efficiency and strengthen its position in the crowded field - the firm is also aiming to further its personalized medicine research
You may also be interested in...
Precision Medicine And The Advent Of The “Niche Buster”: An Interview With GSK’s Paolo Paoletti
The president of GlaxoSmithKline Oncology talked with “The Pink Sheet” about precision medicine, regulatory climate change, the need to provide value for payers and the company’s commitment to double cancer survival globally over the next 10 years.
Last Gasp Or New Life? 2009’s Novel Products Have Blockbuster Potential
After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers the potential for a return of the blockbuster
Last Gasp Or New Life? 2009’s Novel Products Have Blockbuster Potential
After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers the potential for a return of the blockbuster